Matthew M Hsieh

List of Publications by Year
in descending order

81	3,418	159358 30	149479 56
papers	citations	h-index	g-index

82	82	82	3893
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease. New England Journal of Medicine, 2009, 361, 2309-2317.	13.9	381
2	Prevalence of Neutropenia in the U.S. Population: Age, Sex, Smoking Status, and Ethnic Differences. Annals of Internal Medicine, 2007, 146, 486.	2.0	295
3	Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Phenotype. JAMA - Journal of the American Medical Association, 2014, 312, 48.	3.8	277
4	HIFâ€"prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood, 2007, 110, 2140-2147.	0.6	159
5	Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood, 2011, 118, 1197-1207.	0.6	121
6	Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Advances, 2019, 3, 3379-3392.	2.5	121
7	At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood, 2017, 130, 1946-1948.	0.6	119
8	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report. Biology of Blood and Marrow Transplantation, 2017, 23, 538-551.	2.0	112
9	Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. PLoS Medicine, 2017, 14, e1002382.	3.9	107
10	Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?. Cytotherapy, 2009, 11, 464-471.	0.3	105
11	Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Advances, 2020, 4, 2058-2063.	2.5	93
12	Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Advances, 2017, 1, 652-661.	2.5	84
13	Relationship between Mixed Donorâ€"Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 2178-2183.	2.0	74
14	Neutrophil Count in African Americans: Lowering the Target Cutoff to Initiate or Resume Chemotherapy?. Journal of Clinical Oncology, 2010, 28, 1633-1637.	0.8	61
15	Busulfan Produces Efficient Human Cell Engraftment in NOD/LtSz-Scid IL2RÎ³ Null Mice. Stem Cells, 2009, 27, 175-182.	1.4	60
16	Development of a Human Immunodeficiency Virus Type 1-Based Lentiviral Vector That Allows Efficient Transduction of both Human and Rhesus Blood Cells. Journal of Virology, 2009, 83, 9854-9862.	1.5	53
17	Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. British Journal of Haematology, 2007, 139, 504-507.	1.2	52
18	Effect of high-dose plerixafor on CD34 ⁺ cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica, 2017, 102, 600-609.	1.7	51

#	Article	IF	Citations
19	Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease. Seminars in Hematology, 2018, 55, 87-93.	1.8	51
20	Hematopoietic Stem Cell Transplantation for Patients with Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2014, 28, 1171-1185.	0.9	50
21	Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia. PLoS ONE, 2015, 10, e0141706.	1.1	43
22	Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease. Blood, 2016, 128, 1176-1176.	0.6	42
23	Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E689-E696.	3.3	41
24	Nonâ€myeloablative human leukocyte antigenâ€matched related donor transplantation in sickle cell disease: outcomes from three independent centres. British Journal of Haematology, 2021, 192, 761-768.	1.2	41
25	Efficient Generation of Î²-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells from Patients with Sickle Cell Disease. Stem Cells, 2017, 35, 586-596.	1.4	39
26	Pain and opioid use after reversal of sickle cell disease following <scp>HLA</scp>â€matched sibling haematopoietic stem cell transplant. British Journal of Haematology, 2019, 184, 690-693.	1.2	37
27	Chicken HS4 Insulators Have Minimal Barrier Function Among Progeny of Human Hematopoietic Cells Transduced With an HIV1-based Lentiviral Vector. Molecular Therapy, 2011, 19, 133-139.	3.7	36
28	Analyses of genome wide association data, cytokines, and gene expression in African-Americans with benign ethnic neutropenia. PLoS ONE, 2018, 13, e0194400.	1.1	36
29	In mixed hematopoietic chimerism, the donor red cells win. Haematologica, 2011, 96, 13-15.	1.7	34
30	Accelerated lymphocyte reconstitution and long-term recovery afterÂtransplantation of lentiviral-transduced rhesus CD34+ cells mobilizedÂbyÂG-CSF and plerixafor. Experimental Hematology, 2011, 39, 795-805.	0.2	34
31	High-efficiency Transduction of Rhesus Hematopoietic Repopulating Cells by a Modified HIV1-based Lentiviral Vector. Molecular Therapy, 2012, 20, 1882-1892.	3.7	33
32	Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution. Biology of Blood and Marrow Transplantation, 2019, 25, 577-586.	2.0	32
33	High-Efficiency Lentiviral Transduction of Human CD34+ Cells in High-Density Culture with Poloxamer and Prostaglandin E2. Molecular Therapy - Methods and Clinical Development, 2019, 13, 187-196.	1.8	31
34	Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor. Haematologica, 2020, 105, e497.	1.7	29
35	Baseline TP53 mutations in Adults with SCD developing Myeloid Malignancy following Hematopoietic Cell Transplantation. Blood, 2020, 135, 1185-1188.	0.6	29
36	Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts. Experimental Hematology, 2007, 35, 1415-1420.	0.2	26

#	Article	IF	Citations
37	TRIM5Î± Variations Influence Transduction Efficiency With Lentiviral Vectors in Both Human and Rhesus CD34 + Cells In Vitro and In Vivo. Molecular Therapy, 2014, 22, 348-358.	3.7	26
38	Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia. Science Translational Medicine, 2017, 9, .	5.8	26
39	Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study. Lancet Haematology,the, 2017, 4, e553-e561.	2.2	24
40	Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. Blood Advances, 2021, 5, 2403-2411.	2.5	24
41	Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients. Human Gene Therapy Clinical Development, 2017, 28, 136-144.	3.2	23
42	Hematopoietic progenitor cell mobilization is more robust in healthy African American compared to Caucasian donors and is not affected by the presence of sickle cell trait. Transfusion, 2016, 56, 1058-1065.	0.8	22
43	Identification and Clinical Characterization of Children With Benign Ethnic Neutropenia. Journal of Pediatric Hematology/Oncology, 2016, 38, e140-e143.	0.3	21
44	Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders. Nature Communications, 2019, 10, 4479.	5.8	21
45	Integration-specific In Vitro Evaluation of Lentivirally Transduced Rhesus CD34+ Cells Correlates With In Vivo Vector Copy Number. Molecular Therapy - Nucleic Acids, 2013, 2, e122.	2.3	20
46	Fertility after Curative Therapy for Sickle Cell Disease: A Comprehensive Review to Guide Care. Journal of Clinical Medicine, 2022, 11, 2318.	1.0	18
47	Natural history of benign ethnic neutropenia in individuals of African ancestry. Blood Cells, Molecules, and Diseases, 2019, 77, 12-16.	0.6	17
48	Successful Fertility Restoration after Allogenic Hematopoietic Stem Cell Transplantation. Endocrine Practice, 2014, 20, e157-e161.	1.1	16
49	Efficient transduction of human hematopoietic repopulating cells with a chimeric HIV1-based vector including SIV capsid. Experimental Hematology, 2013, 41, 779-788.e1.	0.2	14
50	Reversal of a rheologic cardiomyopathy following hematopoietic stem cell transplantation for sickle cell disease. Blood Advances, 2019, 3, 2816-2824.	2.5	14
51	SENP1, but not fetal hemoglobin, differentiates Andean highlanders with chronic mountain sickness from healthy individuals among Andean highlanders. Experimental Hematology, 2016, 44, 483-490.e2.	0.2	13
52	Hematopoietic stem cell mobilization with plerixafor in sickle cell disease. Haematologica, 2018, 103, 749-750.	1.7	12
53	Neurocognitive functioning in symptomatic adults with sickle cell disease: A description and comparison with unaffected siblings. Neuropsychological Rehabilitation, 2020, 30, 1666-1681.	1.0	11
54	Alternative Donor/Unrelated Donor Transplants for the Î²-Thalassemia and Sickle Cell Disease. Advances in Experimental Medicine and Biology, 2017, 1013, 123-153.	0.8	10

#	Article	IF	Citations
55	High-level embryonic globin production with efficient erythroid differentiation from a K562 erythroleukemia cell line. Experimental Hematology, 2018, 62, 7-16.e1.	0.2	10
56	A Standard Nonmyeloablative Transplantation Regimen for Adults with Sickle Cell Disease: Are We There Yet?. Biology of Blood and Marrow Transplantation, 2016, 22, 397-398.	2.0	8
57	Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia. International Journal of Molecular Sciences, 2018, 19, 681.	1.8	8
58	The impact of pre-existing HLA and red blood cell antibodies on transfusion support and engraftment in sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation from HLA-matched sibling donors: A prospective, single-center, observational study. EClinicalMedicine, 2020, 24, 100432.	3.2	8
59	Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixaforâ€mobilized patients with sickle cell disease. British Journal of Haematology, 2022, 198, 740-744.	1.2	8
60	Kinetics of lentiviral vector transduction in human CD34+ cells. Experimental Hematology, 2016, 44, 106-115.	0.2	7
61	Sickle Cell Anemia and Comorbid Leg Ulcer Treated With Curative Peripheral Blood Stem Cell Transplantation. International Journal of Lower Extremity Wounds, 2017, 16, 56-59.	0.6	6
62	Vibration Controlled Transient Elastography (FibroscanÂ®) in sickle cell liver disease â€•could we strike while the liver is hard?. British Journal of Haematology, 2019, 187, 117-123.	1.2	6
63	Evolution of Gene Therapy, Historical Perspective. Hematology/Oncology Clinics of North America, 2022, 36, 627-645.	0.9	5
64	Incidence of second cancers after allogeneic hematopoietic stem cell transplantation using reduced-dose radiation. Blood, 2009, 114, 225-225.	0.6	4
65	Decitabine Suspends Human CD34+ Cell Differentiation and Proliferation during Lentiviral Transduction. PLoS ONE, 2014, 9, e104022.	1.1	4
66	Diagnostic challenges of prolonged post-treatment clearance of Plasmodium nucleic acids in a pre-transplant autosplenectomized patient with sickle cell disease. Malaria Journal, 2018, 17, 23.	0.8	4
67	Ex vivo immunological evaluation of stable mixed chimeric patients after matched related donor allogeneic transplantation in sickle cell disease. Cytotherapy, 2019, 21, 1206-1215.	0.3	4
68	RNA Trans-Splicing Targeting Endogenous Î²-Globin Pre-Messenger RNA in Human Erythroid Cells. Human Gene Therapy Methods, 2017, 28, 91-99.	2.1	3
69	Increased Rates of Rhabdomyolysis in Male Hematopoietic Cell Transplantation Recipients Taking Sirolimus and Trimethoprim/Sulfamethoxazole. Transplantation and Cellular Therapy, 2021, 27, 1019.e1-1019.e4.	0.6	2
70	Development of a New Generation, Forward-Oriented Therapeutic Vector for Hemoglobin Disorders. Blood, 2016, 128, 1172-1172.	0.6	2
71	At Least 20% Donor Myeloid Chimerism Is Necessary to Reverse the Sickle Phenotype after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 2483-2483.	0.6	2
72	Characterization of Early Lymphocytes Emerging After Nonmyeloablative Conditioning and Hematopoietic Stem Cell Transplant Supported with Sirolimus. Blood, 2012, 120, 4150-4150.	0.6	2

#	Article	IF	Citations
73	Commentary on Winzeler et al â€˜Low arginine vasopressin levels in patients with diabetes insipidus are not associated with anaemiaâ€™. Clinical Endocrinology, 2021, 94, 888-890.	1.2	1
74	Post-Transplant Cyclophosphamide and Sirolimus Are Synergistic in Preventing Rejection and Inducing Stable Mixed Chimerism Independently of Regulatory T Cells.. Blood, 2009, 114, 3540-3540.	0.6	1
75	Hematopoietic Progenitor Cell Mobilization In Response To G-CSF Is More Robust In Healthy African American Compared To Caucasian Donors. Blood, 2013, 122, 696-696.	0.6	1
76	Safety of liver biopsy in patients with sickle cell related liver disease: A singleâ€€center experience. American Journal of Hematology, 2022, 97, .	2.0	1
77	Sickle related events following cardiac catheterisation: risk implication for other invasive procedures. British Journal of Haematology, 2019, 185, 778-780.	1.2	0
78	Factors Affecting Allogeneic Peripheral Blood Stem Cell Mobilization in a Large, Ethnically, Diverse Population.. Blood, 2007, 110, 3283-3283.	0.6	0
79	Acquired Hemophilia A in an African-American Male After Stem Cell Transplant for Sickle Cell Disease: Successful Treatment with Recombinant Porcine Factor VIII (OBI-1) and Tolerance Induction with Rituximab and Prednisone. Blood, 2012, 120, 4631-4631.	0.6	0
80	Peripheral Blood As a Source Of Cells For Regenerative Medicine Applications In Sickle Cell Disease. Blood, 2013, 122, 2209-2209.	0.6	0
81	A Novel Recombinant Eklf-GATA1 Fusion Protein Reduces Sickling of Erythrocytes Cultured from CD34+ Cells with Sickle Cell Disease. Blood, 2016, 128, 3506-3506.	0.6	0